Diseases & Illness | Cancer

Mesothelioma News

New Cancer Drug Targets Only Tumor, Not Normal Tissue

RSS News Feeds
Disease from Products
Toxic Housing Products
Asbestosis
Asbestos
Mesothelioma
 All RSS Feeds

At a glance:

A preliminary clinical trial of a new cancer drug has shown encouraging results. The drug is "monoclonal antibody 806" which is designed to target and attack tumor cells but not normal cells. In the first trials it seems to have done just that, for cancers of several types including mesothelioma, other lung cancers, colorectal cancer and skin cancer. 
 
A drug such as this would have minimal side effects compared to other drugs of its type which do affect normal tissue.

Clinical Trial Confirms Novel EGFR Antibody Targets Tumors But Not ...

PipelineReview.com - 6/7/2006 7:07 AM

New York, NY, USA | Jun 05, 2006 | The Ludwig Institute for Cancer Research (LICR) and Life Science Pharmaceuticals (LSP) today announced the results of the first clinical trial of monoclonal antibody (mAb) 806, which demonstrate that 806 specifically targets epidermal growth factor receptor (EGFR) on a wide range of tumor types but has no uptake by normal tissues. This result is markedly different to other mAbs, which target wild-type (wt) EGFR on normal tissues
 
· Read The Full Mesothelioma Article From PipelineReview.com -->

· Read All Mesothelioma News Stories -->

Comments On Mesothelioma News Articles:


No Current Comments
Posted by Admin on 3/20/2006

There are no current comments. Why not post one?

Leave a Comment:

Once you click the 'Save Comment' button, you will receive a verification email from our website. Be sure to change any spam settings to allow webmaster@lawsuitsearch.com as a trusted sender.
 
If you are already a member, you can Sign In Here.
 
You can create your own FREE user account that you can use to participate in our message boards, blogs, newsletters and other community activities such as this one. To get your FREE user account, click here.

Email Address:

Your Name:

Message Title:

Message: